Anna Orlova

10.3k total citations
290 papers, 8.3k citations indexed

About

Anna Orlova is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Molecular Biology. According to data from OpenAlex, Anna Orlova has authored 290 papers receiving a total of 8.3k indexed citations (citations by other indexed papers that have themselves been cited), including 264 papers in Radiology, Nuclear Medicine and Imaging, 141 papers in Oncology and 70 papers in Molecular Biology. Recurrent topics in Anna Orlova's work include Radiopharmaceutical Chemistry and Applications (213 papers), Monoclonal and Polyclonal Antibodies Research (193 papers) and HER2/EGFR in Cancer Research (93 papers). Anna Orlova is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (213 papers), Monoclonal and Polyclonal Antibodies Research (193 papers) and HER2/EGFR in Cancer Research (93 papers). Anna Orlova collaborates with scholars based in Sweden, Russia and Denmark. Anna Orlova's co-authors include Vladimir Tolmachev, Mattias Sandström, Anders Wennborg, Joachim Feldwisch, Stefan Ståhl, Helena Wållberg, Lars Abrahmsén, Bogdan Mitran, Fredrik Nilsson and Amelie Eriksson Karlström and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Biomaterials.

In The Last Decade

Anna Orlova

277 papers receiving 8.2k citations

Peers

Countries citing papers authored by Anna Orlova

Since Specialization

Citations

This map shows the geographic impact of Anna Orlova's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Orlova with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Orlova more than expected).

Fields of papers citing papers by Anna Orlova

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Orlova. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Orlova. The network helps show where Anna Orlova may publish in the future.

Co-authorship network of co-authors of Anna Orlova

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Orlova. A scholar is included among the top collaborators of Anna Orlova based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Orlova. Anna Orlova is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	First-in-human experience with GRPR antagonist [68Ga]Ga-NOTA-PEG2-RM26 in prostate and breast cancer patients using PET/CT 2025 ·EJNMMI Research ·(unknown), (unknown), Antonios Tzortzakakis, (unknown), Chunde Li, Renske Altena, Cécilia Hindorf, Anna Orlova, Rimma Axelsson, Thuy Tran	2
2	Targeting of Epithelial Cell Adhesion Molecule-Expressing Malignant Tumors Using an Albumin-Binding Domain-Fused Designed Ankyrin Repeat Protein: Effect of the Molecular Architecture 2025 ·International Journal of Molecular Sciences ·Vladimir Tolmachev, Anzhelika Vorobyeva, (unknown), Javad Garousi, (unknown), Torbjörn Gräslund, (unknown), Alexey Schulga, Е. В. Коновалова, Anna Orlova, Sergey M. Deyev, Maryam Oroujeni	1
3	Gastrin-releasing peptide receptor as theranostic target in estrogen-receptor positive breast cancer: A preclinical study of the theranostic pair [55Co]Co- and [177Lu]Lu-DOTA-RM26 2024 ·Nuclear Medicine and Biology ·Christina Baun, Birgitte Brinkmann Olsen, Carla L. Alves, Henrik J. Ditzel, Mikkel G. Terp, Malene Grubbe Hildebrandt, Charlotte Aaberg Poulsen, (unknown), (unknown), Anna Orlova, Johan Hygum Dam, Helge Thisgaard	5
4	GRPR-Antagonists Carrying DOTAGA-Chelator via Positively Charged Linkers: Perspectives for Prostate Cancer Theranostics 2024 ·Pharmaceutics ·(unknown), (unknown), Ayman Abouzayed, A Mattsson, Vladimir Tolmachev, Berthold A. Nock, Θεοδοσία Μάινα, Anna Orlova	5
5	Comparison of approaches for increasing affinity of affibody molecules for imaging of B7-H3: dimerization and affinity maturation 2024 ·EJNMMI Radiopharmacy and Chemistry ·Maryam Oroujeni, (unknown), (unknown), Anna Orlova, Vladimir Tolmachev, Fredrik Y. Frejd	2
6	Preclinical evaluation of new GRPR-antagonists with improved metabolic stability for radiotheranostic use in oncology 2024 ·EJNMMI Radiopharmacy and Chemistry ·(unknown), A Mattsson, Ayman Abouzayed, (unknown), Berthold A. Nock, Vladimir Tolmachev, Θεοδοσία Μάινα, Anna Orlova	3
7	Radionuclide Therapy of HER2-Expressing Xenografts Using [177Lu]Lu-ABY-027 Affibody Molecule Alone and in Combination with Trastuzumab 2023 ·Cancers ·(unknown), Tianqi Xu, Anzhelika Vorobyeva, (unknown), (unknown), Anna Orlova, Fredrik Y. Frejd, Vladimir Tolmachev	13
8	Experimental HER2-Targeted Therapy Using ADAPT6-ABD-mcDM1 in Mice Bearing SKOV3 Ovarian Cancer Xenografts: Efficacy and Selection of Companion Imaging Counterpart 2022 ·Pharmaceutics ·Javad Garousi, Tianqi Xu, (unknown), Olga Vorontsova, Sophia Hober, Anna Orlova, Vladimir Tolmachev, Torbjörn Gräslund, Anzhelika Vorobyeva	3
9	Targeting Tumor Cells Overexpressing the Human Epidermal Growth Factor Receptor 3 with Potent Drug Conjugates Based on Affibody Molecules 2022 ·Biomedicines ·Sara S. Rinne, (unknown), (unknown), Ayman Abouzayed, (unknown), Anzhelika Vorobyeva, John Löfblom, Stefan Ståhl, Anna Orlova, Torbjörn Gräslund	5
10	Effect of Inter-Domain Linker Composition on Biodistribution of ABD-Fused Affibody-Drug Conjugates Targeting HER2 2022 ·Pharmaceutics ·Tianqi Xu, Jie Zhang, Maryam Oroujeni, (unknown), (unknown), М. В. Белоусов, Anna Orlova, Vladimir Tolmachev, Anzhelika Vorobyeva, Torbjörn Gräslund	7
11	Imaging-Guided Therapy Simultaneously Targeting HER2 and EpCAM with Trastuzumab and EpCAM-Directed Toxin Provides Additive Effect in Ovarian Cancer Model 2021 ·Cancers ·Tianqi Xu, Anzhelika Vorobyeva, Alexey Schulga, Е. В. Коновалова, Olga Vorontsova, (unknown), Torbjörn Gräslund, Л. А. Таширева, Anna Orlova, Vladimir Tolmachev, Sergey M. Deyev	11
12	The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy 2021 ·Pharmaceutics ·(unknown), Tianqi Xu, (unknown), Maryam Oroujeni, Jie Zhang, Anzhelika Vorobyeva, Olga Vorontsova, С. В. Вторушин, Vladimir Tolmachev, Torbjörn Gräslund, Anna Orlova	11
13	Targeting HER2 Expressing Tumors with a Potent Drug Conjugate Based on an Albumin Binding Domain-Derived Affinity Protein 2021 ·Pharmaceutics ·Javad Garousi, (unknown), (unknown), Tianqi Xu, Anzhelika Vorobyeva, Maryam Oroujeni, Anna Orlova, Sophia Hober, Torbjörn Gräslund, Vladimir Tolmachev	8
14	Drug Conjugates Based on a Monovalent Affibody Targeting Vector Can Efficiently Eradicate HER2 Positive Human Tumors in an Experimental Mouse Model 2020 ·Cancers ·Tianqi Xu, (unknown), Anzhelika Vorobyeva, Maryam Oroujeni, Anna Orlova, Vladimir Tolmachev, Torbjörn Gräslund	25
15	Preclinical Evaluation of the Copper-64 Labeled GRPR-Antagonist RM26 in Comparison with the Cobalt-55 Labeled Counterpart for PET-Imaging of Prostate Cancer 2020 ·Molecules ·Christina Baun, Bogdan Mitran, Sara S. Rinne, Johan Hygum Dam, Birgitte Brinkmann Olsen, Vladimir Tolmachev, Anna Orlova, Helge Thisgaard	9
16	GMP compliant preparation of a (68)Gallium-labeled Affibody analogue for breast cancer patient examination : first-in-man 2014 ·European Journal of Nuclear Medicine and Molecular Imaging ·Irina Velikyan, Anders Wennborg, Joachim Feldwisch, Anna Orlova, Vladimir Tolmachev, Mark Lubberink, Mattias Sandström, Henrik Lindman, Jörgen Carlsson, Jens Christian Hedemann Sørensen	3
17	Locally Delivered CD40 Agonist Antibody Accumulates in Secondary Lymphoid Organs and Eradicates Experimental Disseminated Bladder Cancer 2013 ·Cancer Immunology Research ·Linda C. Sandin, Anna Orlova, Erika Gustafsson, Peter Ellmark, Vladimir Tolmachev, Thomas H. Tötterman, Sara M. Mangsbo	81
18	Detecting ligand interactions with G protein-coupled receptors in real-time on living cells 2013 ·Biochemical and Biophysical Research Communications ·Bo Xu, Zohreh Varasteh, Anna Orlova, Karl Andersson, Dan Larhammar, Hanna Björkelund	11
19	186Re-maSGS-ZHER2:342, a potential Affibody conjugate for systemic therapy of HER2-expressing tumours 2009 ·European Journal of Nuclear Medicine and Molecular Imaging ·Anna Orlova, Thuy Tran, T. Ekblad, Amelie Eriksson Karlström, Vladimir Tolmachev	36
20	Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors. 2006 ·PubMed ·Anna Orlova, Fredrik Nilsson, Maria Wikman, Charles Widström, Stefan Ståhl, Jörgen Carlsson, Vladimir Tolmachev	73

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact